Evidence map›Paper›PMID 39073415›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Traditional Chinese medicine combined with chemotherapy in the treatment of advanced non-small cell lung cancer: key drug screening and mechanism analysis.

Yu Tang, Zhengping Xian, Fengjiao Wu, Hongyu Cao, Lihao Wang, Qian Tang, Yanan Du, Xuefang Zheng

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Combination Therapy ofIntegrative cancer therapies
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yu TangCollege of Life and Health, Dalian University, Dalian, 116622, China.
Zhengping XianCollege of Life and Health, Dalian University, Dalian, 116622, China.
Fengjiao WuCollege of Life and Health, Dalian University, Dalian, 116622, China.
Hongyu CaoCollege of Life and Health, Dalian University, Dalian, 116622, China.
Lihao WangCollege of Environmental and Chemical Engineering, Dalian University, Dalian, 116622, China.
Qian TangCollege of Life and Health, Dalian University, Dalian, 116622, China. tangqian@dlu.edu.cn.
Yanan DuCollege of Environmental and Chemical Engineering, Dalian University, Dalian, 116622, China.
Xuefang ZhengLiaoning Key Laboratory of Bio-Organic Chemistry, Dalian University, Dalian, 116622, China. dlxfzheng@126.com.

Funding

Dalian University DLUXK-2023-YB-007National Natural Science Foundation of China NO. 21571025National Natural Science Foundation of China No.21601024National Natural Science Foundation of China No.21601025
6 · The paper itself

Abstract

In the course of clinical treatment for anti-tumor, the combination of traditional Chinese medicine (TCM) and other treatment schemes can reduce toxicity and increase efficiency. The purpose of this paper is to find out the key TCM and effective components for the treatment of non-small cell lung cancer (NSCLC) and analyze its therapeutic mechanism by analyzing the prescription of TCM combined with chemotherapy for NSCLC. Firstly, the prescriptions of TCM in the randomized controlled trials combined with chemotherapy for NSCLC were collected, and the core TCM was screened by frequency statistics, association rule analysis, and cluster analysis. Then, the intersection targets of the potential effects of NSCLC and core Chinese medicine were collected, and PPI analysis and enrichment analysis were performed on the intersection targets to screen the core targets, components, and pathways. The core components were verified by molecular docking and cell experiments. In this study, 269 prescriptions were collected, among which the frequency of medication for Astragalus membranaceus (HQ, in Chinese), Wolfiporia cocos (FL, in Chinese), and Atractylodes macrocephala (BZ, in Chinese) was over 100. Association rule analysis showed that they were highly correlated and clustered into the same category in cluster analysis. Their core components were quercetin, kaempferol, and isorhamnetin. The molecular docking results of the core components with the core targets AKT1 and EGFR obtained by PPI network analysis showed that they could bind stably. KEGG analysis screened 110 pathways including PI3K-Akt; the results of CCK-8 showed that quercetin, kaempferol, and isorhamnetin could effectively inhibit the proliferation of A549 cells, and isorhamnetin had the best inhibitory effect. Isorhamnetin can inhibit the migration and invasion of A549 cells, induce apoptosis and G1 phase arrest, and decrease the expression of P-PI3K and P-AKT in A549 cells. In a word, the key TCM for the treatment of NSCLC includes HQ, FL, and BZ. and its key components quercetin, kaempferol, and isorhamnetin have potential therapeutic effects on NSCLC according to the research results.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungDrugs, Chinese HerbalLung NeoplasmsMedicine, Chinese TraditionalHumansMolecular Docking SimulationRandomized Controlled Trials as TopicDrugs, Chinese HerbalExperimental validationMedication rulesMolecular dockingNetwork pharmacologyNon-small cell lung cancerTraditional Chinese medicine

Identifiers

PMID39073415

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.